Format

Send to

Choose Destination
Science. 2010 Jan 15;327(5963):331-4. doi: 10.1126/science.1179907. Epub 2009 Nov 26.

Tetrathiomolybdate inhibits copper trafficking proteins through metal cluster formation.

Author information

1
The Chemistry of Life Processes Institute, Northwestern University, Evanston, IL 60208, USA.

Abstract

Tetrathiomolybdate (TM) is an orally active agent for treatment of disorders of copper metabolism. Here we describe how TM inhibits proteins that regulate copper physiology. Crystallographic results reveal that the surprising stability of the drug complex with the metallochaperone Atx1 arises from formation of a sulfur-bridged copper-molybdenum cluster reminiscent of those found in molybdenum and iron sulfur proteins. Spectroscopic studies indicate that this cluster is stable in solution and corresponds to physiological clusters isolated from TM-treated Wilson's disease animal models. Finally, mechanistic studies show that the drug-metallochaperone inhibits metal transfer functions between copper-trafficking proteins. The results are consistent with a model wherein TM can directly and reversibly down-regulate copper delivery to secreted metalloenzymes and suggest that proteins involved in metal regulation might be fruitful drug targets.

PMID:
19965379
PMCID:
PMC3658115
DOI:
10.1126/science.1179907
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center